Centre of Excellence in Tumor Genetics Research

Bidragets beskrivning

Cancer is a challenge as not only environmental factors play an important role but every tumor has a unique genome. We aim at understanding its function to bring genomic medicine into practice. We do this by using public data and by creating and analyzing new datasets from selected materials. So far we have; Developed tools to explore the human genome; Characterized a new hereditary condition predisposing to blood neoplasia; Identified genetic changes associated with prognosis of prostate cancer, and genomic drivers of treatment resistance in metastatic disease; Provided evidence for a role of a bacterial genotoxin in cancer; Achieved a breakthrough in understanding genesis of uterine fibroids. Our findings in the study of early-onset cancers can be used in counselling, and population-based registry data can be used to assess equity in the national health-care system. Findings on the trends of colorectal cancer incidence highlight the need for public health efforts in prevention.
Visa mer

Startår

2023

Slutår

2025

Beviljade finansiering

Jussi Taipale Orcid -palvelun logo
1 958 430 €





Rollen i Finlands Akademis konsortium

Övriga parter i konsortiet

Partner
Tammerfors universitet (352818)
846 542 €
Partner
314 666 €
Leader
Helsingfors universitet (352814)
2 516 362 €
Leader
Helsingfors universitet (352814)
2 516 362 €

Finansiär

Finlands Akademi

Typ av finansiering

Program för spetsforskningsenheter

Övriga uppgifter

Finansieringsbeslutets nummer

352817

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Biolääketieteet

Identifierade teman

cancer